CORE--TRANSGENIC ANIMAL MODELS

$0P01FY2001CANIH

University Of California San Francisco, San Francisco CA

Investigators

Linked publications & trials

Paper 23477410 Paper 23400595 Paper 20505003 Paper 20371345 Paper 20223936 Paper 20215503 Paper 20145119 Paper 20138013 Paper 20121209 Paper 19906309 Paper 19892798 Paper 19805121 Paper 19647220 Paper 19477127 Paper 19297327 Paper 19138167 Paper 18698413 Paper 18627343 Paper 18514224 Paper 18363999 Paper 18359864 Paper 18343672 Paper 18340378 Paper 18328425 Paper 18199546 Paper 18056472 Paper 17981566 Paper 17946000 Paper 17828252 Paper 17671208 Paper 17663247 Paper 17620340 Paper 17545601 Paper 17524981 Paper 17475279 Paper 17440987 Paper 17392479 Paper 17276050 Paper 17265430 Paper 17158762 Paper 17136575 Paper 17119035 Paper 17096566 Paper 17069009 Paper 16895390 Paper 16854378 Paper 16798735 Paper 16740631 Paper 16672242 Paper 16637611 Paper 16524717 Paper 16520377 Paper 16481467 Paper 16374453 Paper 16331886 Paper 16113679 Paper 16007225 Paper 15994223 Paper 15911377 Paper 15841177 Paper 15839837 Paper 15833851 Paper 15771225 Paper 15661339 Paper 15550552 Paper 15494398 Paper 15158963 Paper 15123647 Paper 15075248 Paper 14996727 Paper 14705961 Paper 14663466 Paper 14612405 Paper 14569063 Paper 14529371 Paper 14515175 Paper 12970191 Paper 12923547 Paper 12842087 Paper 12815038 Paper 12675519 Paper 12649383 Paper 12549907 Paper 12490959 Paper 12443789 Paper 12426511 Paper 12401493 Paper 12376553 Paper 12368295 Paper 12119356 Paper 12119354 Paper 12091880 Paper 12062105 Paper 11959867 Paper 11923519 Paper 11861813 Paper 11856036 Paper 11798065 Paper 11782944 Paper 11687497

Abstract

The objective of this core is to develop, breed and provide new transgenic mouse strains to be used for in vivo studies in the laboratory programs. The core will provide transgenic mice expression TIMP-1, ecotin and/or cystatins under constitutive and regulated promoters bred onto FVB/N and immunocompromised backgrounds, and humanized transgenic mice expressing human metalloproteinases under control of endogenous human promoters. The core will breed specific metalloprotease or inhibitor null-mutant mice onto backgrounds suitable for use in studies with isogenic and xenogenic cancer models. These models will lead to assessment of the pathogenesis and potential antiprotease therapy with greater specificity than animal models currently available.

View original record on NIH RePORTER →